The multiple myelomas—current concepts in cytogenetic classification and therapy
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
[HTML][HTML] Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow (BM) and represents
the second most common hematological malignancy in the world. The MM tumor …
the second most common hematological malignancy in the world. The MM tumor …
[HTML][HTML] Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma
A Chari, MC Minnema, JG Berdeja… - … England Journal of …, 2022 - Mass Medical Soc
Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …
[HTML][HTML] Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma
PG Richardson, S Trudel, R Popat… - … England Journal of …, 2023 - Mass Medical Soc
Background Despite recent progress, multiple myeloma remains incurable. Mezigdomide is
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …
[HTML][HTML] Oral selinexor–dexamethasone for triple-class refractory multiple myeloma
Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab
and isatuximab, has significantly impacted the management of patients with multiple …
and isatuximab, has significantly impacted the management of patients with multiple …
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Despite treatment advances, patients with multiple myeloma (MM) often progress through
standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs …
standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs …
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase …
Background Pomalidomide and dexamethasone is a standard of care for patients with
multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE …
multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE …
Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma
PG Richardson, A Oriol, A Larocca, J Bladé… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that
targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor …
targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor …
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double …
Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces
apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has …
apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has …